LYZEUM LTD

What LYZEUM LTD does

Lyzeum Ltd is a privately held Cambridge, UK-based company that develops AI-driven software for automated diagnosis of coeliac disease from duodenal (small intestinal) biopsies. The company's core technology applies computer vision and multiple-instance learning to digitised whole-slide images, segmenting villi, crypts, intraepithelial lymphocytes, and enterocytes, and computing IEL-to-enterocyte and villus-to-crypt ratios to produce interpretable diagnostic outputs. Published validation reports accuracy, sensitivity, and specificity exceeding 95%, with the company claiming its models are trained on the largest duodenal biopsy dataset globally. The product is positioned as clinical-grade decision support for pathologists, framed against an NHS context in which only 3% of pathology departments are fully staffed and inter-observer agreement on coeliac diagnosis is around 80%.

The company's go-to-market is enterprise-focused, targeting NHS pathology departments and hospital clinical teams via direct sales rather than consumer or SMB channels. Revenue, if any, is implied to come from software licensing or subscription arrangements with healthcare institutions, although no pricing, contracts, or paying customers are publicly disclosed. Lyzeum is operating pre-commercially, with public-facing activity centred on peer-reviewed publications (NEJM AI, BMJ Digital Health, BMJ Open Gastroenterology, Scientific Reports, Journal of Pathology Informatics) and academic collaborations rather than sales or regulatory milestones.

Lyzeum's competitive position rests on its data assets, its multi-disciplinary team (NHS pathologists, Cambridge mathematicians and engineers), and its academic partnerships with the University of Cambridge, UKRI, Addenbrooke's Hospital NHS, and University Hospital Southampton NHS Foundation Trust. Leadership comprises Professor Elizabeth Soilleux (CEO, NHS pathologist), Dr Florian Jaeckle (CTO), and Graham Snudden (COO), with Professors Mark Arends and Carola-Bibiane Schönlieb as scientific advisors. The firm has 1-10 employees, no disclosed funding rounds, and no certifications, UKCA / CE marking, or commercial deployment signals.

Name

LYZEUM LTD

Legal name

Lyzeum Ltd

Website

https://lyzeumltd.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Lyzeum Ltd is a Cambridge-based AI company developing clinical-grade machine learning software that automates coeliac disease diagnosis from duodenal biopsies, primarily for NHS pathology departments and hospital clinical teams in the UK.

Ownership category

akta.pro rank

Product category

Digital Pathology AI Software

NAICS

Software Publishers (5132)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software (HLACANAD)

akta.pro secondary industries

Medical Imaging AI (HDAAAEAH), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)

Keywords

• Digital pathology software
• AI diagnostic tools
• Medical imaging AI
• Clinical decision support
• Pathology workflow software

Headquarters

HQ city

Cambridge

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. AI Diagnostic Software Licensing: Clinical-grade AI software deployed to support pathologists' workflow in NHS pathology departments and healthcare systems. Revenue likely generated through enterprise licensing agreements with healthcare institutions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Lyzeum Ltd develops a clinical-grade AI software system that analyses digitised whole-slide images of duodenal (small intestinal) biopsies to diagnose coeliac disease, supporting pathologists' workflow. The platform uses deep learning and multiple-instance learning models trained on the largest duodenal dataset globally, achieving accuracy, sensitivity, and specificity exceeding 95%, and is positioned for deployment within NHS pathology departments and hospital clinical teams.

Product overview

Lyzeum Ltd offers a unified AI-based diagnostic platform for coeliac disease detection. Built on the largest duodenal biopsy dataset globally, the clinical-grade AI analyzes digitized whole-slide images of duodenal biopsies to support pathologists' workflow and improve accuracy and efficiency of diagnosis. The system segments villi, crypts, intraepithelial lymphocytes, and enterocytes, and provides interpretable coeliac disease diagnoses with accuracy, sensitivity, and specificity exceeding 95%. This is a single integrated product rather than a modular platform.

Differentiator

Problem solved

Functional benefit

Products and services

• AI-based Coeliac Disease Diagnostic System A clinical-grade AI software system that analyses digitised whole-slide images of duodenal (small intestinal) biopsies to diagnose coeliac disease for pathologists working within NHS pathology departments and hospital clinical teams. The system uses deep learning and multiple-instance learning models to segment villi, crypts, intraepithelial lymphocytes (IELs), and enterocytes and produces interpretable diagnoses with quantified ratios (IEL-to-enterocyte and villus-to-crypt ratios), achieving accuracy, sensitivity, and specificity exceeding 95%.

Quantifiable outcome

• 95%+ accuracy, sensitivity, and specificity in coeliac disease diagnosis
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

Five partnerships are on record, tiered core and major.

• University of CambridgecoreStrategic or Co-development PartnerAcademic partnership with the Department of Pathology and the Centre for Mathematical Sciences at University of Cambridge. Cambridge University mathematicians and engineers collaborate with NHS pathologists to develop machine learning models for coeliac disease diagnosis. Professor Carola-Bibiane Schönlieb serves as a scientific advisor.
• UK Research and Innovation (UKRI)coreStrategic or Co-development PartnerResearch collaboration with UKRI, a UK government body that funds research and innovation across sciences and humanities. Logo displayed as collaborator indicating research partnership.
• Addenbrooke's Hospital NHScoreStrategic or Co-development PartnerClinical partnership with Addenbrooke's Hospital NHS, providing access to pathology expertise and clinical data. NHS pathologists from Addenbrooke's are part of Lyzeum's multi-disciplinary team, including Professor Elizabeth Soilleux as CEO.
• University Hospital Southampton NHS Foundation TrustmajorStrategic or Co-development PartnerClinical partnership with University Hospital Southampton NHS Foundation Trust for pathology research and development collaboration. Logo displayed as collaborator.
• NHS Pathology DepartmentscoreStrategic or Co-development PartnerMulti-disciplinary team includes NHS pathologists working in conjunction with the company. The AI technologies are designed to support pathologists' workflow across NHS pathology departments to address the 3% fully staffed challenge.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Ibex Medical Analytics: Ibex develops AI-powered diagnostic software for pathology (breast, prostate, GI biopsies), making it a direct competitor in clinical-grade AI that analyses whole-slide images to support pathologist workflows in hospitals and reference labs.
• PathAI: PathAI builds AI tools for pathology diagnosis and biomarker analysis, including gastrointestinal applications, and partners with pharma and diagnostics companies; it competes with Lyzeum in deploying AI to improve diagnostic accuracy on biopsy images.
• Paige: Paige develops AI-based clinical-grade applications for cancer diagnosis from digital pathology slides, with FDA-authorised products, and competes with Lyzeum in the broader digital diagnostic pathology space.

Emerging players

• Owkin: Owkin applies AI to pathology and clinical research, partnering with academic medical centers and pharma; it has overlapping digital pathology ambitions with Lyzeum, particularly around hospital data collaborations.
• Tribun Health: Tribun Health (formerly Tribun) provides AI-augmented digital pathology solutions including diagnostic support modules used in European hospitals, making it a relevant competitor in EU pathology AI deployments.
• Aiosyn: Aiosyn develops AI solutions for digital pathology with a focus on biomarker quantification in clinical workflows, making it an emerging competitor in specialised tissue-based AI diagnostics.
• Proscia: Proscia offers a digital pathology platform with AI applications for routine pathology workflows, targeting hospital and reference lab customers with similar enterprise sales motions to Lyzeum's NHS pathology focus.

Broad incumbents

• Philips Digital Pathology: Philips provides an enterprise digital pathology solution spanning imaging hardware, image management, and AI-enabled applications, making it an incumbent platform that hospitals may prefer over a single-application vendor.
• Google Health (Verily / Google DeepMind): Google Health, Verily and DeepMind have published foundational pathology AI research and explore clinical applications, representing a broad incumbent threat with deep resources that could generalise into Lyzeum's GI biopsy niche.
• Roche (Roche Digital Pathology): Roche offers an end-to-end digital pathology platform (scanners, workflow software, AI partnerships) and is a broad incumbent whose installed base and AI partner ecosystem could outcompete point solutions like Lyzeum in NHS tenders.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/lyzeumltd
• LinkedInlinkedin.com/company/lyzeumltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LYZEUM LTD